AbbVie presents New, Late Breaking Investigational Data at 2018 at AAD Annual meeting

AbbVie  a global research and development-based biopharmaceutical company, today announced it will present new, late-breaking data across investigational medicines and HUMIRA® (adalimumab) at the 2018 American Academy of Dermatology (AAD) Annual Meeting (February 16-20, San Diego).

“We continuously seek to improve the care of patients living with chronic dermatologic diseases,” said Marek Honczarenko, M.D., Ph.D., vice president, Immunology development, AbbVie. “We believe that delivering the highest quality care starts with the patient. For the first time, we are pleased to present our research from three different targets to address chronic skin conditions in the dermatology community – both through long-term HUMIRA research and new investigational agents risankizumab and upadacitinib.”

During the “Late-breaking Research: Clinical Trials” session, AbbVie will present data from ultIMMa-1 and ultIMMA-2, two replicate Phase 3 clinical trials evaluating the safety and efficacy of risankizumab, an investigational IL-23 inhibitor, compared to placebo or STELARA® (ustekinumab) for the treatment of patients with moderate to severe plaque psoriasis. AbbVie plans to submit risankizumab for the treatment of moderate to severe plaque psoriasis to regulatory authorities in 2018.

In the same session, AbbVie will also share results from a Phase 2b trial of upadacitinib, an investigational oral JAK1-selective inhibitor, evaluating safety and efficacy in patients with moderate to severe atopic dermatitis. Risankizumab and upadacitinib are not approved by regulatory authorities and safety and efficacy have not been established.

Additionally, AbbVie will present HUMIRA data including:

• Eight-year interim analyses from the ESPRIT 10-year post-marketing surveillance registry of HUMIRA in patients with moderate to severe chronic plaque psoriasis, which will include real-world effectiveness of skin clearance data.
• An analysis of long-term safety and efficacy in patients with fingernail psoriasis.
• Patient-reported outcomes from the HUMIRA pivotal studies in hidradenitis suppurativa (HS), and research evaluating HS and surgical outcomes.
  HUMIRA is one of the most comprehensively-studied biologics available for immune-mediated inflammatory diseases, and is supported by more than 20 years of clinical trial experience in immunology.1